Last reviewed · How we verify
NCT07007611
The Role of Surgical Resection AND Stereotactic Radiosurgery in Primary Central Nervous System -Diffuse Large B Cell Lymphoma
trial in Primary Central Nervous System Diffusing Large Cell Lymphoma in 76 participants. Completed in 1 May 2025.
1 December 2023
Quick facts
| Lead sponsor | jiahong Deng |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 76 |
| Start date | 1 December 2006 |
| Primary completion | 1 December 2023 |
| Estimated completion | 1 May 2025 |
Conditions studied
- Primary Central Nervous System Diffusing Large Cell Lymphoma — all drugs for Primary Central Nervous System Diffusing Large Cell Lymphoma →
Sponsor
jiahong Deng
Who can join
Eligibility, any sex, with Primary Central Nervous System Diffusing Large Cell Lymphoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The objective of this observational study is to understand the long-term impact of surgery and gamma knife treatment on primary central diffuse large B-cell lymphoma. The main questions it aims to answer are: Can surgery and gamma knife prolong the survival period of patients with primary central diffuse large B-cell lymphoma? Participants who have already incorporated surgery and gamma knife as part of the routine medical care for patients with primary central diffuse large B-cell lymphoma will answer questions about survival period within 5 years.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT07007611
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07007611 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by jiahong Deng
- Last refreshed: 11 June 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07007611.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing